UNSPSC 51112516: Melphalan flufenamide

This classification denotes a nitrogen mustard compound C24H30Cl2FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F70C5K4786, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)-l-phenylalanyl-4-fluoro-, ethyl ester, but more generally known as melphalan flufenamide, which bears US NIH Compound Identifier 9935639. Most nations, for tariff and trade purposes, schedule melphalan flufenamide under HS 29224995 and SITC 51465. As of Q4 2014, MELPHALAN FLUFENAMIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCOC(=O)[C@H](CC1CCC(CC1)F)NC(=O)[C@H](CC2CCC(CC2)N(CCCL)CCCL)N.

UNSPSC 51112516 Melphalan flufenamide is a Commodity code representing a specific pharmaceutical product — an anti-cancer agent used in multiple myeloma treatment — that state and local procurement offices acquire through pharmacy benefit programs, state Medicaid systems, and health plans serving public employees and retirees. State and local governments do not typically solicit this drug as a direct commodity purchase; instead, they procure access to it through broader pharmacy benefit management contracts, group purchasing organization agreements, or direct manufacturer relationships negotiated at the state health agency level. The issuing bodies active under this code are state health and human services departments managing Medicaid, state employee health plans, and related pharmacy benefit initiatives.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs as part of a Therapeutic Pharmacy Initiative. The RFI explored vendors' capacity to establish direct contracts with self-insured employee group health plans and state agencies outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels, with emphasis on negotiated net pricing and outcomes-based agreement models. This preliminary market intelligence effort indicates Texas HHS intent to reshape its pharmacy procurement strategy before issuing a formal Request for Proposal. No recent opportunities from other state or local jurisdictions appear in the source; the code shows limited recent activity beyond Texas's exploratory initiative.